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Background  
Patients with pancreatic ductal adenocarcinoma (PDAC) are subject to poor outcomes, with a median overall 
survival of 6-12 months in patients treated with palliative chemotherapy for metastatic disease. Appropriate 
patient selection for palliative chemotherapy is therefore critical to avoid detrimental outcomes1. Although CA 19-
9 is the only recommended biomarker for clinical use in PDAC, it is not routinely used as a predictive marker of 
response to chemotherapy. We hypothesised that falls in CA 19-9 > 50% at the end of chemotherapy are 
associated with improved survival outcomes.  
 
Method 
We conducted a retrospective review of patients treated with palliative chemotherapy for metastatic PDAC over a 
9-year period, at two separate university teaching hospitals in London, UK (n = 179).  Median progression free 
(PFS) and overall survival (OS) were correlated with patient specific factors including CA 19-9, gender, age, 
number of visceral sites affected, previous surgical / adjuvant therapy and palliative chemotherapy.  
 
Results  
93% of patients had an elevated CA 19-9 at diagnosis. Median PFS and OS were significantly greater when 
serum CA 19-9 fell > 50% from the initiation of chemotherapy to the end of treatment.  Patients demonstrating a 
fall in CA 19-9 >50%, who received 1 line of palliative chemotherapy, had a median PFS of 5.3 months compared 
with 3 months for patients who did not (p= <0.001), regardless of whether they received subsequent lines of 
chemotherapy.  Patients only receiving 1 line of chemotherapy with a fall in CA 19-9 >50% had a PFS of 4.5 
months, compared with 2.9 months (p= 0.005).  
 
In patients who received 1st line chemotherapy (n=150), median OS was 5.6 months, when associated with a fall 
in CA 19-9 >50%, compared with 5.3 months (p= 0.017). Similarly, those who received 2nd line chemotherapy 
(n=29) had an OS of 16 months versus 13.4 months (p= 0.703). Compared with the other measured variables, 
for 1st line treatment, this was an independent prognostic factor in multivariate analysis. We also demonstrated 
that the higher the level of CA 19-9, both prior to chemotherapy and at the end of treatment, the poorer the 
prognosis and earlier the relapse. Those with pre-treatment CA 19-9 levels between 0-100 kU/L had a median 
OS of 6.9 months (p= 0.034) compared with 4.6 months (p= <0.001), when greater than 1000 kU/L.  
 
Conclusion 
We demonstrate that patients receiving chemotherapy with lower baseline CA 19-9 levels and reductions > 50% 
at the end of treatment are associated with improved survival outcomes. Regular CA 19-9 testing should be used 
to aid decision making in these patients. These results should be validated with prospective data from 
randomised clinical trials of patients undergoing palliative chemotherapy for metastatic PDAC.  
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